版本:
中国

BRIEF-Horizon Pharma Plc to acquire River Vision Development Corp

May 8 Horizon Pharma Plc:

* Horizon Pharma Plc announces agreement to acquire River Vision Development Corp and teprotumumab (rv001), a biologic in late-stage development for rare eye disease

* Horizon Pharma Plc - pivotal trial of teprotumumab in thyroid eye disease (ted) expected to begin in second half of 2017

* Horizon Pharma Plc - deal for upfront cash payment of $145 million

* Horizon Pharma - Horizon anticipates a potential peak annual sales opportunity for Teprotumumab, if approved, in excess of $250 million in United States Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐